NEW YORK (GenomeWeb) – Almac Diagnostic Services and precision oncology pharma TP Therapeutics said today that are collaborating to develop and commercialize a next-generation sequencing companion diagnostic for TP's repotrectinib, an investigational tyrosine kinase inhibitor targeting ROS1, NTRK1-3 and ALK gene fusions in advanced solid tumors.